HTG Molecular Diagnostics and Oncologie Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

HTG Molecular Diagnostics (Nasdaq:HTGM) a provider of instruments, reagents, and services for molecular profiling applications and Oncologie an innovative biotechnology company with operations in Boston and Shanghai, today announced the completion of a master agreement where the companies have agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline.

As quoted in the press release:

“We are honored to be working with Oncologie on biomarker development programs for their innovative pipeline of Immuno-oncology assets,” stated TJ Johnson HTG Chief Executive Officer. “HTG is committed to the development of NGS-based precision diagnostics to support biomarker driven drug development, and we share a common focus with Oncologie in the field of Immuno-oncology.”

Laura Benjamin Ph.D., Oncologie Chief Executive Officer and founder added, “We believe HTG’s technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally.”

Click here to read the full press release.